Pravin U. Dugel, MD, discusses the HAWK and HARRIER studies, particularly with regard to whether the disease activity assessment done at week 16 can predict which patients can be extended to 12 weeks. He also explains why this is important from a clinical standpoint. Interview from the 2018 ARVO Annual Meeting where leading experts recap the hottest presentations and panel discussions.